Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Revance Therapeutics ( (RVNC) ) has issued an update.
On February 6, 2025, Revance Therapeutics finalized a merger with Crown Laboratories, resulting in the delisting of Revance’s common stock from NASDAQ and significant changes to the company’s equity awards and convertible notes. This merger, initiated by a tender offer at $3.65 per share, culminated in Crown Laboratories acquiring approximately 82% of Revance’s outstanding shares, with Revance continuing as the surviving corporation. The transaction led to a restructuring of Revance’s board and executive positions, with Crown’s executives assuming leadership roles.
More about Revance Therapeutics
YTD Price Performance: 19.28%
Average Trading Volume: 3,209,000
Technical Sentiment Consensus Rating: Strong Buy
Current Market Cap: $381M
Find detailed analytics on RVNC stock on TipRanks’ Stock Analysis page.
Trending Articles:
- “The No. 1 Destination for the Most Talented Artists”: Netflix Stock (NASDAQ:NFLX) Notches Up as the Duffer Brothers Consider Jumping Ship
- “Breakthrough EVs”: Ford Stock (NYSE:F) Notches Up on New Battery Details
- “An Equity Stake”: Intel Stock (NASDAQ:INTC) Surges as U.S. Government May Buy In With CHIPS Act Money